肉瘤AYA患者的5年生存率:孟加拉国的一项前瞻性固定队列研究

IF 56.7 1区医学 Q1 ONCOLOGY Annals of Oncology Pub Date : 2023-11-01 DOI:10.1016/j.annonc.2023.09.206

Abdullah Al Mamun Khan, Muhammed Jahangir Alam, Parvin Shahida Akhtar

{"title":"肉瘤AYA患者的5年生存率:孟加拉国的一项前瞻性固定队列研究","authors":"Abdullah Al Mamun Khan, Muhammed Jahangir Alam, Parvin Shahida Akhtar","doi":"10.1016/j.annonc.2023.09.206","DOIUrl":null,"url":null,"abstract":"Survivors of adolescent and young adult cancers (AYA) often live 50 to 60 years beyond their diagnosis but a few clinical and epidemiological data from developing countries. Sarcoma is a leading and worst malignancy that may manageable if diagnosed early.","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"61 6","pages":"0"},"PeriodicalIF":56.7000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MO20-5 Five-year survival rate of AYA patients from sarcoma: A prospective fixed cohort study in Bangladesh\",\"authors\":\"Abdullah Al Mamun Khan, Muhammed Jahangir Alam, Parvin Shahida Akhtar\",\"doi\":\"10.1016/j.annonc.2023.09.206\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Survivors of adolescent and young adult cancers (AYA) often live 50 to 60 years beyond their diagnosis but a few clinical and epidemiological data from developing countries. Sarcoma is a leading and worst malignancy that may manageable if diagnosed early.\",\"PeriodicalId\":8000,\"journal\":{\"name\":\"Annals of Oncology\",\"volume\":\"61 6\",\"pages\":\"0\"},\"PeriodicalIF\":56.7000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.annonc.2023.09.206\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.annonc.2023.09.206","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

青少年和年轻成人癌症(AYA)的幸存者通常在诊断后活50至60年，但发展中国家的临床和流行病学数据很少。肉瘤是一种主要和最严重的恶性肿瘤，如果早期诊断可能是可控的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

MO20-5 Five-year survival rate of AYA patients from sarcoma: A prospective fixed cohort study in Bangladesh

Survivors of adolescent and young adult cancers (AYA) often live 50 to 60 years beyond their diagnosis but a few clinical and epidemiological data from developing countries. Sarcoma is a leading and worst malignancy that may manageable if diagnosed early.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Oncology 医学-肿瘤学

CiteScore

63.90

自引率

1.00%

发文量

3712

审稿时长

2-3 weeks

期刊介绍： Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, offers rapid and efficient peer-reviewed publications on innovative cancer treatments and translational research in oncology and precision medicine. The journal primarily focuses on areas such as systemic anticancer therapy, with a specific emphasis on molecular targeted agents and new immune therapies. We also welcome randomized trials, including negative results, as well as top-level guidelines. Additionally, we encourage submissions in emerging fields that are crucial to personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Manuscripts related to radiotherapy, surgery, and pediatrics will be considered if they demonstrate a clear interaction with any of the aforementioned fields or if they present groundbreaking findings. Our international editorial board comprises renowned experts who are leaders in their respective fields. Through Annals of Oncology, we strive to provide the most effective communication on the dynamic and ever-evolving global oncology landscape.